AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(ii)).
“March 31, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) received an additional written notice of non-compliance (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires stockholders’ equity of $4.0 million or more if a listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reporte”
Earnings Releases
AEON Biopharma, Inc. reported financial results for the year ended December 31, 2025.
“On March 30, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the year ended December 31, 2025.”
Jost Fisher changed role as Interim President and Chief Executive Officer at AEON Biopharma, Inc..
“Jost Fisher will step down as Interim President and Chief Executive Officer but will continue to serve as chairman of the Board, a member of the audit committee and chair of the compensation committee.”
Robert Bancroft was appointed as Chief Executive Officer, President and Principal Executive Officer at AEON Biopharma, Inc..
“On April 19, 2025, the board of directors (the “Board”) of AEON BioPharma, Inc. (the “Company”) appointed Robert Bancroft, age 60, as the Company’s Principal Executive Officer, President, Chief Executive Officer and member of the Board to serve as a Class I director, effective as of April 29, 2025.”
Jennifer Sy was appointed as Chief Accounting Officer and principal financial officer at AEON Biopharma, Inc..
“On April 3, 2025, the Board appointed Jennifer Sy, age 40, as the Company’s Chief Accounting Officer and principal financial officer, effective as of April 4, 2025.”
Jost Fischer was appointed as Interim President, Chief Executive Officer and principal executive officer at AEON Biopharma, Inc..
“On April 3, 2025, the Board formally appointed Mr. Fischer to serve as Interim President, Chief Executive Officer and principal executive officer of the Company, effective as of April 4, 2025.”
Jost Fischer was appointed as Interim Chief Executive Officer at AEON Biopharma, Inc..
“The Board has named Jost Fischer, the current Chairman of the Board, to serve as Interim CEO following Mr. Forth’s departure while the Board identifies a replacement CEO.”
Marc Forth resigned as President and Chief Executive Officer at AEON Biopharma, Inc..
“On March 24, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) was notified by Marc Forth that he intended to resign as the Company’s President and Chief Executive Officer (“CEO”) in order to pursue another opportunity.”
Listing & Compliance Notices
AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).
“February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w”
Jennifer Sy was appointed as principal accounting officer at AEON Biopharma, Inc..
“On May 16, 2024, our Board of Directors appointed Jennifer Sy, age 39, as our principal accounting officer, effective as of May 17, 2024.”
Marc Forth was appointed as principal financial officer at AEON Biopharma, Inc..
“On May 16, 2024, our Board of Directors appointed Marc Forth, age 53, as our principal financial officer, effective as of May 17, 2024.”
Peter Reynolds was terminated as Chief Financial Officer at AEON Biopharma, Inc..
“On May 16, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) terminated the Consulting Agreement (the “Agreement”) between AEON and Peter Reynolds, which has resulted in his termination as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company effective as of May 17, 2024.”
Earnings Releases
AEON Biopharma, Inc. reported financial results for the first quarter ended March 31, 2024.
“AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the fiscal quarter ended March 31, 2024.”
Auditor Changes
AEON Biopharma, Inc. reported that prior financial statements should not be relied upon.
“The Company's management and the Board have discussed the matters described herein with KPMG LLP, the Company's independent registered public accounting firm. The identified error had no impact on the Company’s cash balances or operating cash flows for the quarter ended September 30, 2023 nor the year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.